NASDAQ:RVPH

Reviva Pharmaceuticals Stock Forecast, Price & News

$4.18
+0.10 (+2.45 %)
(As of 04/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.09
Now: $4.18
$4.30
50-Day Range
$4.05
MA: $6.29
$8.75
52-Week Range
$3.93
Now: $4.18
$15.10
Volume8,458 shs
Average Volume30,293 shs
Market Capitalization$38.61 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.04
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. Its lead product candidate is RP5063 that has completed Phase II clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials for treating bipolar disorder, major depressive disorder, behavioral and psychotic symptoms, dementia or Alzheimer's disease, parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis; and RP1208 that has completed pre-clinical development studies for the treatment of depression and obesity. The company is based in Cupertino, California.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RVPH
CUSIPN/A
CIKN/A
Phone408 501 8881
Employees5
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash Flow$0.03 per share
Book Value$0.60 per share

Profitability

Net Income$620,000.00

Miscellaneous

Market Cap$38.61 million
Next Earnings Date5/3/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

0.17 out of 5 stars

Medical Sector

1828th out of 2,025 stocks

Pharmaceutical Preparations Industry

730th out of 772 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
$4.18
+0.10 (+2.45 %)
(As of 04/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RVPH News and Ratings via Email

Sign-up to receive the latest news and ratings for RVPH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Reviva Pharmaceuticals (NASDAQ:RVPH) Frequently Asked Questions

What stocks does MarketBeat like better than Reviva Pharmaceuticals?

Wall Street analysts have given Reviva Pharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Reviva Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Reviva Pharmaceuticals?

Reviva Pharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 10,900 shares, an increase of 240.6% from the March 15th total of 3,200 shares. Based on an average daily volume of 31,600 shares, the short-interest ratio is presently 0.3 days. Approximately 0.2% of the shares of the company are sold short.
View Reviva Pharmaceuticals' Short Interest
.

When is Reviva Pharmaceuticals' next earnings date?

Reviva Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, May 3rd 2021.
View our earnings forecast for Reviva Pharmaceuticals
.

Who are Reviva Pharmaceuticals' key executives?

Reviva Pharmaceuticals' management team includes the following people:
  • Dr. Laxminarayan Bhat, Founder, CEO, Pres & Director (Age 55, Pay $247.95k)
  • Mr. Narayan Prabhu, Chief Financial Officer (Age 49)
  • Dr. Marc Cantillon, Chief Medical Officer (Age 62)

Who are some of Reviva Pharmaceuticals' key competitors?

What is Reviva Pharmaceuticals' stock symbol?

Reviva Pharmaceuticals trades on the NASDAQ under the ticker symbol "RVPH."

How do I buy shares of Reviva Pharmaceuticals?

Shares of RVPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Reviva Pharmaceuticals' stock price today?

One share of RVPH stock can currently be purchased for approximately $4.18.

How much money does Reviva Pharmaceuticals make?

Reviva Pharmaceuticals has a market capitalization of $38.61 million.

How many employees does Reviva Pharmaceuticals have?

Reviva Pharmaceuticals employs 5 workers across the globe.

What is Reviva Pharmaceuticals' official website?

The official website for Reviva Pharmaceuticals is www.revivapharma.com.

How can I contact Reviva Pharmaceuticals?

The company can be reached via phone at 408 501 8881.


This page was last updated on 4/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.